Pharmacodynamics of cefepime in patients with Gram-negative infections
Pharmacodynamics of cefepime in patients with Gram-negative infections
复制标题
DOI：
10.1093/jac/dkf130
复制
发表时间：
2002-09-01
影响因子：
5.2
通讯作者：
Drusano, GL
中科院分区：
文献类型：
--
作者：
Tam, VH;McKinnon, PS;Drusano, GL
我们进行了一项前瞻性、开放标签研究，以描述36名接受头孢吡肟治疗的患者的暴露与结局之间的关系。20例患者记录了革兰氏阴性菌感染。在稳态下采集定时血液和尿液样本，以确定药代动力学和药效学参数。微生物学成功与头孢吡肟浓度超过4.3 x MIC的给药间隔比例显著相关。我们的研究结果支持体外数据，表明β-内酰胺类药物的杀菌活性在类似于4 × MIC的浓度下最优化。这些结果应通过大型前瞻性临床试验进行验证。
We conducted a prospective, open-label study to delineate a relationship between exposure and outcomes in 36 patients treated with cefepime. Twenty patients had documented Gram-negative infections. Timed blood and urine samples were obtained at steady state to determine pharmacokinetic and pharmacodynamic parameters. Microbiological success was significantly correlated with the proportion of the dosing interval that cefepime concentrations exceeded 4.3 x MIC. Our results support in vitro data that suggest bactericidal activity of beta-lactams is optimized at concentrations similar to4 x MIC. These results should be validated by large prospective clinical trials.